Adma Biologics (ADMA) EBIAT (2011 - 2025)
Adma Biologics posted quarterly EBIAT of $49.4 million for Q4 2025, down 55.87% year-on-year from $111.9 million in Q4 2024, and up 35.55% on a QoQ basis from $36.4 million in Q3 2025.
Adma Biologics (ADMA) has 13 years of EBIAT data on file, last reported at $49.4 million in Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 55.87% year-over-year to $49.4 million; the trailing twelve-month figure through Dec 2025 stood at $146.9 million (down 25.67% YoY), and the FY2025 full-year result was $146.9 million, down 25.67% from the prior year.
- EBIAT for Q4 2025 stood at $49.4 million, up from $36.4 million in the prior quarter.
- Across five years, EBIAT topped out at $111.9 million in Q4 2024 and bottomed at -$25.0 million in Q1 2022.
- The 5-year median for EBIAT is -$6.6 million (2023), against an average of $8.9 million.
- The widest annual swing landed in 2024, when EBIAT surged 1299.96%; it then tumbled 55.87% in 2025.
- A 5-year view of EBIAT shows it stood at -$16.6 million in 2021, then grew by 26.54% to -$12.2 million in 2022, then tumbled by 44.26% to -$17.6 million in 2023, then surged by 734.15% to $111.9 million in 2024, then sank by 55.87% to $49.4 million in 2025.
- The last three EBIAT figures came in at $49.4 million (Q4 2025), $36.4 million (Q3 2025), and $34.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Adma Biologics | 1.90 Bn | 1.81 Bn | 88.82 Mn | 49.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 49.38 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 34.22 Mn |
| Mar 31, 2025 | 26.90 Mn |
| Dec 31, 2024 | 111.90 Mn |
| Sep 30, 2024 | 35.91 Mn |
| Jun 30, 2024 | 32.06 Mn |
| Mar 31, 2024 | 17.81 Mn |
| Dec 31, 2023 | -17.65 Mn |
| Sep 30, 2023 | 2.57 Mn |
| Jun 30, 2023 | -6.37 Mn |
| Mar 31, 2023 | -6.79 Mn |
| Dec 31, 2022 | -12.23 Mn |
| Sep 30, 2022 | -14.90 Mn |
| Jun 30, 2022 | -13.76 Mn |
| Mar 31, 2022 | -25.01 Mn |
| Dec 31, 2021 | -16.65 Mn |
| Sep 30, 2021 | -17.71 Mn |
| Jun 30, 2021 | -18.91 Mn |
| Mar 31, 2021 | -18.38 Mn |
| Dec 31, 2020 | -19.41 Mn |
| Sep 30, 2020 | -16.92 Mn |
| Jun 30, 2020 | -20.18 Mn |
| Mar 31, 2020 | -19.25 Mn |
| Dec 31, 2019 | -10.38 Mn |
| Sep 30, 2019 | -11.44 Mn |
| Jun 30, 2019 | -13.21 Mn |
| Mar 31, 2019 | -13.07 Mn |
| Dec 31, 2018 | -17.93 Mn |
| Sep 30, 2018 | -15.14 Mn |
| Jun 30, 2018 | -14.75 Mn |
| Mar 31, 2018 | -17.82 Mn |
| Dec 31, 2017 | -11.76 Mn |
| Sep 30, 2017 | -15.20 Mn |
| Jun 30, 2017 | -9.04 Mn |
| Mar 31, 2017 | -6.54 Mn |
| Dec 31, 2016 | -4.56 Mn |
| Sep 30, 2016 | -4.33 Mn |
| Jun 30, 2016 | -6.01 Mn |
| Mar 31, 2016 | -4.61 Mn |
| Mar 31, 2013 | -3.24 Mn |
| Dec 31, 2012 | -2.25 Mn |
| Sep 30, 2012 | -3.25 Mn |
| Jun 30, 2012 | -1.21 Mn |
| Mar 31, 2012 | -597,314.00 |
| Dec 31, 2011 | -8,328.00 |
| Sep 30, 2011 | -981,077.00 |
| Jun 30, 2011 | -2.39 Mn |
| Mar 31, 2011 | -1.58 Mn |